Picture of Y-mAbs Therapeutics logo

YMAB Y-mAbs Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapHigh Flyer

Y-mAbs Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

* Y-mAbs Therapeutics Inc  YMAB.OQ  reported a quarterly
adjusted
loss of 16 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -18 cents.  The mean expectation of
eight analysts for the quarter was for a loss of 16 cents per
share. Wall Street expected results to range from -24 cents
to -9 cents per share.
    * Revenue fell 9.7% to $18.46 million from a year ago;
analysts
expected $23.26 million. 
    * Y-mAbs Therapeutics Inc's reported EPS for the quarter was
a
loss of 16 cents​.
    * The company reported a quarterly loss of $7 million.
    * Y-mAbs Therapeutics Inc shares had risen by 18.3% this
quarter and gained 128.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 11.2%
in the last three months.​ 
    * In the last 30 days, two analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Y-mAbs
Therapeutics Inc is 21.50 
This summary was machine generated from LSEG data November 8 at
04:24 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.16          -0.16          Met
 Jun. 30 2024      -0.13          -0.21          Missed
 Mar. 31 2024      -0.14          -0.15          Missed
 Dec. 31 2023      -0.20          -0.02          Beat

Recent news on Y-mAbs Therapeutics

See all news